MA34581B1 - Systèmes thérapeutiques transdermiques à feuille de protection inhibant la cristallisation (release liner) - Google Patents
Systèmes thérapeutiques transdermiques à feuille de protection inhibant la cristallisation (release liner)Info
- Publication number
- MA34581B1 MA34581B1 MA35706A MA35706A MA34581B1 MA 34581 B1 MA34581 B1 MA 34581B1 MA 35706 A MA35706 A MA 35706A MA 35706 A MA35706 A MA 35706A MA 34581 B1 MA34581 B1 MA 34581B1
- Authority
- MA
- Morocco
- Prior art keywords
- release liner
- transdermal therapeutic
- therapeutic systems
- protective sheet
- inhibiting crystallization
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010040299A DE102010040299A1 (de) | 2010-09-06 | 2010-09-06 | Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner) |
| PCT/EP2011/065204 WO2012031985A1 (de) | 2010-09-06 | 2011-09-02 | Transdermale therapeutische systeme mit kristallisationsinhibierender schutzfolie (release liner) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34581B1 true MA34581B1 (fr) | 2013-10-02 |
Family
ID=44653285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35706A MA34581B1 (fr) | 2010-09-06 | 2011-09-02 | Systèmes thérapeutiques transdermiques à feuille de protection inhibant la cristallisation (release liner) |
Country Status (33)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI630208B (zh) | 2008-12-08 | 2018-07-21 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
| GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH674618A5 (cg-RX-API-DMAC7.html) * | 1987-04-02 | 1990-06-29 | Ciba Geigy Ag | |
| ATE132751T1 (de) | 1988-10-27 | 1996-01-15 | Schering Ag | Mittel zur transdermalen applikation enthaltend gestoden |
| US5512292A (en) | 1990-10-29 | 1996-04-30 | Alza Corporation | Transdermal contraceptive formulations methods and devices |
| WO1992007590A1 (en) | 1990-10-29 | 1992-05-14 | Alza Corporation | Transdermal contraceptive formulations, methods and devices |
| DE4210711A1 (de) | 1991-10-31 | 1993-05-06 | Schering Ag Berlin Und Bergkamen, 1000 Berlin, De | Transdermale therapeutische systeme mit kristallisationsinhibitoren |
| DE4336557C2 (de) | 1993-05-06 | 1997-07-17 | Lohmann Therapie Syst Lts | Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung |
| DE4405899A1 (de) * | 1994-02-18 | 1995-08-24 | Schering Ag | Mittel zur transdermalen Applikation enthaltend Desogestrel |
| DE4405898A1 (de) | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
| US5762956A (en) | 1996-04-24 | 1998-06-09 | Rutgers, The State University Of New Jersey | Transdermal contraceptive delivery system and process |
| DE19629468A1 (de) * | 1996-07-11 | 1998-01-15 | Schering Ag | Transdermale therapeutische Systeme |
| DE19827732A1 (de) * | 1998-06-22 | 1999-12-23 | Rottapharm Bv | Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie |
| DE19906152B4 (de) | 1999-02-10 | 2005-02-10 | Jenapharm Gmbh & Co. Kg | Wirkstoffhaltige Laminate für Transdermalsysteme |
| KR100758757B1 (ko) | 1999-11-24 | 2007-09-14 | 애자일 쎄라퓨틱스, 인크. | 개량된 경피적 피임제 송달시스템 및 송달방법 |
| DE10053375C1 (de) * | 2000-10-27 | 2002-01-24 | Lohmann Therapie Syst Lts | Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen |
| TWI287455B (en) | 2000-12-05 | 2007-10-01 | Noven Pharma | Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use |
| EP1216699A1 (de) | 2000-12-21 | 2002-06-26 | Schering Aktiengesellschaft | Transdermalsystem enthaltend ein hochpotentes Gestagen |
| US20030165547A1 (en) * | 2001-05-18 | 2003-09-04 | Elisabeth Picard-Lesboueyries | Cosmetic uses of 3beta-acetoxy-7-oxo-DHEA |
| DE10261696A1 (de) * | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
| EA008098B1 (ru) * | 2003-02-21 | 2007-02-27 | Шеринг Акциенгезельшафт | Стойкий к уф-излучению трансдермальный пластырь |
| MXPA06006682A (es) | 2003-12-12 | 2006-08-11 | Schering Ag | Hormonas de administracion transdermica que no necesitan potenciadores de penetracion. |
| UA89766C2 (en) * | 2003-12-12 | 2010-03-10 | Байер Шеринг Фарма Акциенгезельшафт | Transdermal delivery system of gestodene |
| US8668925B2 (en) * | 2003-12-12 | 2014-03-11 | Bayer Intellectual Property Gmbh | Transdermal delivery of hormones without the need of penetration enhancers |
| WO2006044206A2 (en) * | 2004-10-08 | 2006-04-27 | Noven Pharmaceuticals, Inc. | Transdermal drug delivery device including an occlusive backing |
| DE102004062182B4 (de) | 2004-12-20 | 2007-06-06 | Bayer Schering Pharma Ag | Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff |
| US8962013B2 (en) * | 2005-05-02 | 2015-02-24 | Bayer Intellectual Property Gmbh | Multi-layered transdermal system with triazine UV absorber |
| DE102005050729A1 (de) | 2005-10-19 | 2007-04-26 | Schering Ag | Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption |
| CA2739380C (en) * | 2008-10-06 | 2014-12-09 | Mylan Technologies, Inc. | Amorphous rotigotine transdermal system |
-
2010
- 2010-09-06 DE DE102010040299A patent/DE102010040299A1/de not_active Withdrawn
-
2011
- 2011-02-09 UA UAA201304320A patent/UA110217C2/ru unknown
- 2011-09-02 EP EP11757808.8A patent/EP2613771A1/de not_active Withdrawn
- 2011-09-02 WO PCT/EP2011/065204 patent/WO2012031985A1/de not_active Ceased
- 2011-09-02 SG SG2013013453A patent/SG187941A1/en unknown
- 2011-09-02 AP AP2013006787A patent/AP3586A/xx active
- 2011-09-02 JP JP2013526490A patent/JP6104800B2/ja not_active Expired - Fee Related
- 2011-09-02 AU AU2011298892A patent/AU2011298892B2/en not_active Ceased
- 2011-09-02 EA EA201390246A patent/EA032575B1/ru not_active IP Right Cessation
- 2011-09-02 MY MYPI2013700339A patent/MY162768A/en unknown
- 2011-09-02 BR BR112013005305A patent/BR112013005305A2/pt not_active Application Discontinuation
- 2011-09-02 CN CN201180042701.6A patent/CN103079549B/zh not_active Expired - Fee Related
- 2011-09-02 NZ NZ607630A patent/NZ607630A/en not_active IP Right Cessation
- 2011-09-02 MA MA35706A patent/MA34581B1/fr unknown
- 2011-09-02 SG SG10201506927TA patent/SG10201506927TA/en unknown
- 2011-09-02 KR KR1020137008726A patent/KR20130114127A/ko not_active Ceased
- 2011-09-02 PE PE2017001638A patent/PE20180198A1/es not_active Application Discontinuation
- 2011-09-02 PH PH1/2013/500429A patent/PH12013500429A1/en unknown
- 2011-09-02 MX MX2013002602A patent/MX2013002602A/es active IP Right Grant
- 2011-09-02 CU CU20130031A patent/CU24172B1/es active IP Right Grant
- 2011-09-02 PE PE2013000383A patent/PE20131138A1/es not_active Application Discontinuation
- 2011-09-02 CA CA2810103A patent/CA2810103C/en active Active
- 2011-09-05 UY UY0001033590A patent/UY33590A/es unknown
- 2011-09-06 TW TW100132149A patent/TWI576245B/zh not_active IP Right Cessation
- 2011-09-06 AR ARP110103250A patent/AR082907A1/es unknown
- 2011-09-06 US US13/225,660 patent/US8557279B2/en not_active Expired - Fee Related
-
2013
- 2013-02-22 ZA ZA2013/01389A patent/ZA201301389B/en unknown
- 2013-02-28 IL IL224980A patent/IL224980A/en not_active IP Right Cessation
- 2013-03-05 TN TNP2013000087A patent/TN2013000087A1/fr unknown
- 2013-03-06 GT GT201300062A patent/GT201300062A/es unknown
- 2013-03-06 EC ECSP13012477 patent/ECSP13012477A/es unknown
- 2013-03-06 CO CO13045117A patent/CO6690753A2/es unknown
- 2013-03-06 CL CL2013000636A patent/CL2013000636A1/es unknown
- 2013-03-06 DO DO2013000053A patent/DOP2013000053A/es unknown
- 2013-03-06 CR CR20130098A patent/CR20130098A/es unknown
- 2013-09-17 US US14/028,990 patent/US9060955B2/en not_active Expired - Fee Related
-
2016
- 2016-08-22 JP JP2016161929A patent/JP2016216500A/ja active Pending
-
2017
- 2017-03-13 IL IL251124A patent/IL251124B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120888T1 (el) | Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες | |
| MA34474B1 (fr) | Agonistes de gpr40 | |
| CL2008001839A1 (es) | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. | |
| WO2008049657A3 (de) | Verwendung von (meth)acrylat-copolymeren in retard-arzneiformen zur verringerung des einflusses von ethanol auf die wirkstofffreisetzung | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
| IN2012MN02923A (cg-RX-API-DMAC7.html) | ||
| WO2011116139A3 (en) | Improved pharmaceutical compositions comprising cck- 8 and methods of delivery | |
| BRPI0516718B8 (pt) | formulação de liberação modificada de ibuprofeno fornecendo liberação imediata e prolongada do fármaco | |
| ATE554770T1 (de) | Therapeutisches mittel gegen entzündliche darmerkrankungen | |
| MY172303A (en) | Compositions and methods of use of phorbol esters | |
| BR112013002280A2 (pt) | composições farmacêuticas orais de liberação controlada compreendendo blonanseina | |
| UA109290C2 (uk) | Спільні кристали і солі інгібіторів ccr3 | |
| CL2013003630A1 (es) | Formulacion farmaceutica liquida que comprende nitisinona y un tampon de acido citrico que tien un ph en el rango de 2,5 a 3,5, de preferencia 3,0; y su uso para el tratamiento de tirosemia, enfermedad de parkinson, depresion, entre otros. | |
| MA38694A2 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
| CA2602573A1 (en) | Protective agent for retinal neuronal cell containing prostaglandin f2 .alpha. derivative as active ingredient | |
| RU2014129620A (ru) | Композиции, содержащие аморфный эмодепсид | |
| MA34581B1 (fr) | Systèmes thérapeutiques transdermiques à feuille de protection inhibant la cristallisation (release liner) | |
| MX2023014877A (es) | Composiciones y metodos de uso para tratar inflamacion aberrante en glandulas secretoras perioculares o en la superficie ocular. | |
| PH12018501876A1 (en) | Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | |
| FR2987271B1 (fr) | Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens | |
| FR3014692B1 (fr) | Compositions pharmaceutiques orales a retention gastrique. | |
| PH12013501910B1 (en) | Solid ambroxol-containing preparation | |
| MA38093A1 (fr) | Formulations à libération modifiée pour l'oprozomib | |
| TH111755A (th) | ไทรอะโซโลพิริดาซีนในรูปสารยับยั้ง par 1, การเตรียมของสารเหล่านั้นและการใช้สารเหล่านั้นเป็นยา |